中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Metabolic Diseases Exploratory Indications
  • Pipeline
    Pipeline Clinical Trials
  • Partnership
  • Investors
    Financials & Filing
  • News
  • Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Show More
    2014
  • Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

    2024-12-18

  • Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

    2024-11-12

  • Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

    2024-11-07

  • Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

    2024-09-17

  • Gannex Announces Poster Presentation Describing Positive Interim 12-Week Results from Ongoing 52-Week Phase II Clinical Trial of Once-Daily ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

    2024-06-11

  • ​Ascletis Announces Strategic Decisions on FXR agonist ASC42

    2024-04-03

  • Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

    2024-03-11

  • Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

    2024-01-24

  • Gannex’s Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

    2024-01-23

  • Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

    2024-01-02

  • © 2018 Ascletis Pharma Inc.
  • All Rights Reserved

contact

  • pr@ascletis.com
  • bd@ascletis.com
  • hr@ascletis.com
  • clinicaltrials@ascletis.com

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号 浙ICP备11050387号-1